



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/647,982	08/26/2003	Paul S. Kaytes	01313.US1	3612
25533 75	590 01/05/2006		EXAM	INER
PHARMACIA & UPJOHN			MYERS, CARLA J	
301 HENRIET 0228-32-LAW	TA ST		ART UNIT	PAPER NUMBER
KALAMAZOO, MI 49007			1634	· _ · · · · · · . ·
			DATE MAILED: 01/05/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/647,982	KAYTES ET AL.
Office Action Summary	Examiner	Art Unit
	Carla Myers	1634
The MAILING DATE of this communication Period for Reply	appears on the cover sheet wi	th the correspondence address
A SHORTENED STATUTORY PERIOD FOR REWHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication - If NO period for reply is specified above, the maximum statutory pe - Failure to reply within the set or extended period for reply will, by s Any reply received by the Office later than three months after the nearned patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNION R 1.136(a). In no event, however, may a red. r. eriod will apply and will expire SIX (6) MON tatute, cause the application to become AB	CATION. eply be timely filed ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on _ 2a) This action is FINAL. 2b) 3) Since this application is in condition for all closed in accordance with the practice und	This action is non-final. owance except for formal matt	•
Disposition of Claims		
4) Claim(s) 1-56 is/are pending in the applica 4a) Of the above claim(s) is/are with 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-56 are subject to restriction and	ndrawn from consideration.	
Application Papers		
9) The specification is objected to by the Exar 10) The drawing(s) filed on is/are: a) Applicant may not request that any objection to Replacement drawing sheet(s) including the co 11) The oath or declaration is objected to by the	accepted or b) objected to the drawing(s) be held in abeyan rection is required if the drawing	nce. See 37 CFR 1.85(a). (s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for force a) All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the application from the International Bu * See the attached detailed Office action for a	nents have been received. nents have been received in A priority documents have been reau (PCT Rule 17.2(a)).	pplication No received in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SE) Paper No(s 3/08) 5) D Notice of Ir	Summary (PTO-413) s)/Mail Date nformal Patent Application (PTO-152)
Paper No(s)/Mail Date	·	

U.S. Patent and Trademark Office PTOL-326 (Rev. 7-05) Application/Control Number: 10/647,982 Page 2

Art Unit: 1634

Election/Restrictions

1. Prior to setting forth the restriction requirement, it is pointed out that Applicants have presented the claims in improper Markush format. See Ex-parte Markush, 1925 C.D. 126 and In-re-Weber, 198 USPQ 334. The claims are improperly joined as the claimed methods require the detection of distinct target molecules, i.e. distinct polymorphisms. A reference against one target molecule would not be a reference against the other target molecule. Therefore, the restriction will be set forth for each of the various groups, irrespective of the improper format of the claims, because the claims do not recite proper species. Upon election, Applicants are required to amend the claims to set forth only the elected inventive groups.

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-56, drawn to methods for diagnosing a propensity for schizophrenia by detecting a haplotype consisting of the polymorphic sites 601 and 2106, classified in Class 435, subclass 6.
 - II. Claims 1-56, drawn to methods for diagnosing a propensity for schizophrenia by detecting a haplotype consisting of the polymorphic sites 194 and 2106, classified in Class 435, subclass 6.
 - III-XXVII. Claims 1-56, drawn to methods for diagnosing a propensity for schizophrenia by detecting a haplotype consisting of one of the polymorphic sites set forth in (3)-(25) of claim 1 or (3)-(27) of claim 29, classified in Class 435, subclass 6.
- 3. The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1634

Inventions I-XXVII are drawn to patentably distinct method, each requiring the detection of distinct haplotype. Each polymorphic site within SEQ ID NO: 1 and each combination of polymorphisms is chemically and structurally distinct from one another. For example, a polymorphism at position 601 of SEQ ID NO: 1 is chemically, structurally and functionally distinct from a polymorphism at position 194 of SEQ ID NO: 1. Further, each haplotype is distinct from the other because the haplotypes consist of structurally distinct polymorphisms and each haplotype has a different effect. As set forth in the specification, each haplotype is present in populations of affected schizophrenia individuals and in control populations at different frequencies. For instance, with the S1(194)/S4 (1038)haplotype, the A/C polymorphisms were more prevalent in affected individuals as compared to the control individuals, while for the \$6(2106)/\$4(1038) haplotype, the A/G alleles were more prevalent in affected individuals as compared to the control individuals. Thereby, the effect of the S4 allele varies depending on whether the allele is considered together with the S1 allele or with the S6 allele. Similarly, with the S1/S4 haplotype, the A/C polymorphisms were more prevalent in affected individuals as compared to the control individuals, while for the S1/S2 haplotype, the G/G alleles were more prevalent in affected individuals as compared to the control individuals. Thereby, the effect of the S1 allele varies depending on whether the allele is considered together with the S4 allele or with the S2 allele. It is expected that each of the haplotypes will also be present in other disease populations and control populations at varying frequencies. Accordingly, each of the claimed methods for detecting a particular haplotype or combination of haplotypes is considered to be patentably distinct

from one another. In response to the restriction requirement, Applicants should state the particular haplotype or combination of haplotypes that is elected.

- 4. These inventions are distinct for the reasons given above and have acquired a different status in the art as recognized divergent subject matter. Further, a search for inventions I-XXVII require different keyword and sequence searches that are not coextensive. For example, a search for the methods which detect the polymorphisms at positions 601 and 2106 would require different keyword and sequence searches as compared to a search for methods which detect the polymorphisms 194, 1038 and 2185. Additionally, a finding that the method of invention I is novel and unobvious would not necessarily extend to a holding that the method of invention II is also novel and unobvious. Similarly, a finding that the methods of invention I were known or would have been obvious would not necessarily extend to a holding that the methods of invention II were also known and obvious. Accordingly, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.
- 5. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by

Application/Control Number: 10/647,982

Art Unit: 1634

a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Page 5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is (571) 272-0747. The examiner can normally be reached on Monday-Thursday from 6:30 AM-5:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (571)-272-0745.

The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free).

Carla Myers December 28, 2005

CARLA J. MYERS ?
PRIMARY EXAMINER